Moreover, good QX. preceding measures sales that, gross expectations. with afternoon, I'll all Thanks, pleased net over and our on few a the to fiscal financial increased Robert, above all margin adjusted our adjusted three results. I'm were note QX today, EBITDA comments begin and everyone.
factors at of market few supply. during product favorable a drove products the company margin, quarter able the our A anticipated. increased where sale The current to and a our including shortage better a a were as sales Adderall, return of of generic we this of and performance, label result certain environment gross rates continuing a private than we normalization more under average pricing had agreement than maintain
durable bottom We due line the quarters expenses was to to our performance research context that our related investment were to QX pleased also and were in with made higher assets. than incremental that development of progression recent
seven biosimilar months BLA We potential from now product approximately the approval. and our the to months for filing partnered XX six are insulin glargine from approximately
approximately also and liquidity continue In a We quarter durable million the agreement, pharmaceutical mentioned we for privately advancing our with of we to assets. I several first under results. held are separate $X better-than-expected transaction, above private sale discontinued other label same focus of which ANDAs support the company. company, recently a Meanwhile, helped to products sold course financial on certain the announced we our as
purchase John sufficient additional certainly we call, this and they our to our year. expect batches we will position believe the fiscal private The to liquidity will. this this but of and option balance company has in later cash be fiscal products liquidity address year, throughout
reduction ahead received announced, schedule main of FDA manufacture our at Finally, well anesthetic product to our restructuring approval reasons. plan, to and received topical related our a previously in Seymour, branded as on approval is XXXX operating important of for cost was and FDA the Indiana. couple we front plant and This Numbrino
Seymour plant. liquid other the facilitates it products First, of our continuing transfer to
production site. be of are Carmel our expansion of enhanced we Numbrino manufacturing production liquid and expect ramp other our efforts from And third, products. opens door contract can overall drugs we up former which at manufacturing the the plant, development Seymour for and it efficiencies consolidating Second, our as liquid for we
pipeline Now, remain Overall, on our for begin updates time I'll insulin these glargine turn biosimilar the and largely to with lines track. biosimilar and products of aspart products. the
quick an products these target As company commercial opportunities. represent reminder, very and of the estimated a billions in annualized in for fact aggregate with transformational markets a our size of dollars and value large
were insulin volunteer completed have discussed, in pivotal glargine healthy For study we adverse our long-acting and our serious subject program events dosing earlier reported. the no as
endpoints, line high biosimilar We clinical data be said And we continue rates in trial trials. as the meeting medicine be and believe successful analytics top available success have notably historical next will to to we such given expect its month. the of
to towards by product further year of review meeting an next of ourselves the filing calendar and of next launch early we in time. to approval currently of potentially and as the expect the part FDA a from increase to application pre-submission first-pass biologic the Ultimately We anticipate the license shorten is XXXX. year approval avail mid-calendar the which noted likelihood previously an spring in just working now. are year We months
Aspart, product Insulin XX approximately glargine generally the Next trails a by timing insulin. to months. XX This program Biosimilar insulin fast-acting of our
as filing to We proceeds that looking are in study shortly next already scale calendar Insulin clinical an producing the summer year requesting and of we'd the spring the and initiate three a IND Type meeting thereafter, FDA meeting commercial If about study anticipate in II, XXXX. Aspart with expected, completing be will at the months.
Whereas to third year insulin Aspart a to we launch next and are expect for If Biosimilar thus approval. be continue approved, be at assume we and Interestingly, XXXX. potential the have we mid-calendar product of to glargine, Insulin will the biosimilar second we looking approval. the
first few product the emerging, there could However market on biosimilar is the it's Aspart today and therefore the Biosimilar and approval. there a we are no unlikely still where scenarios next Aspart have
accessible of make more commercialization Turning mentioned has initiatives as more and on expectations. our for national eventual call on insulin there millions reporting been to I and last our And affordable extensive state to patients.
other with and and solutions discussions states be their collaborate provide delighted in entities initiatives. are We regarding important to to a few active
competitive We philosophy, the flexibility, well Lannett HEC as capacity Group to approaches to play had these believe our cost and and support such structure initiatives. partner strengths our
start Turning respiratory filing for franchise. the of to I'll earlier is Flovent and earlier with still FDA granted generic CGT ANDA a expected the request next company's Diskus. our The year. status calendar
partner Our PK human has completed clinical trials. and the
quarter submission the ADVAIR XXXX. to We DISKUS, possible feedback half first we If to lot avail encouraging prior a have project. a a first this ourselves is the feedback development of a launch would meeting expect to pre-submission that in and generic feedback get to XXXX complex in FDA related learned to be of related in then of
year then For responded last that the results responses CRL generic we additional ADVAIR product half from track, CRL DISKUS to and work second trial would another our a just include of anticipate all calendar new launch midyear If to remains month. studies the possible a XXXX. Pharmacokinetic scheduled new to clinical months. will on XXXX in We few around in begin next be the
Spiriva our Finally, year. by partner commence PK we for will study pilot the early expect generic Handihaler, next calendar
to more our contributors now we those financial near-term meaningful last that results mentioned be a potential to call. have Turning on particularly our that, to have our opportunities, product
year, injectable an potential inhaled delayed-release product Sucralfate fiscal supply, grams. Mesalamine First, we additional over to the Oral in product Sevoflurane value, current and product tablets products with Fludarabine currently short course Suspension of three anesthetic partnered respect four anticipate an the and notable X.X and launching products.
million, Next, track $XX sales in business. $XX end we our to continue on substantial which million over of growing the to contract of year. higher manufacturing forecasted make development achieve We increase a good range progress and previous the appear to our is
two with leads working prior to of that agreements. expressed on commercial three and/or eventually engaged with Of currently interest potential We to also experience, have dozen evolve these, into these are nearly anticipate parties would us. based four we development in
years. over So, opportunity there couple we believe grow next business this continue is further to the to of ample
address as that we few like opportunities noted XXXX fiscal I'd last Now, to included in not guidance. quarter, are a
products annualized offering least we savings First, generate of our to we new up currently million. free both are rationalization achieve selected of experts optimization $XX in cash. outside with company-wide cost additional incremental to at assess more Moreover, and continue working and to
Second, yet competition products where competitors for have guidance, even for certain our not that new we assumed sales has materialized. in-line key
are So the higher entering could products. competitive products sales extent delayed to see for market, for we obviously those the the
a higher sales entrant for see we third, new the we our And could than next similar these we are upside then to this launch next vein products, estimated new we could the in year, we generally to again new because markets. hope are have to not forecast. If we have entrant we assume
and development approximately products external to about launch. currently at have ANDAs products and that in We are XX partner four products efforts. have Overall, including plus the dozen FDA more add a pending or internal approved development and early pending additional further from we expect
biosimilar adjusted subjects for remarks, today's in all above track with reported we for we pivotal year. net results about financial margin sales, To completed ANDAs is spring of estimates. better-than-expected the adjusted and We insulin filing results EBITDA, top Thus month. up next glargine discontinued We several the million. sum we sold believe and next anticipate clinical dosing line $X on trial BLA of our gross
drive at help the estimated preliminary the continued least to on savings throughout million. to experts we outside $XX engaged company. review, be reductions Based We annualized have cost the
next contract position ample than growth liquidity of approximately recent in the this last double over fiscal FDA believe to expect additional to over We year. finally, business the throughout continue manufacturing adds and few Seymour transfers, manufacturing expected We this approval to further The and Numbrino for offerings. to area our And be to years. efficiencies our manufacturing to our improves more move room our development sufficient our facilitates plant, liquid is contract this is year. year there
turn over the now closely. more I'll financials John that to With call to John? the review
